Future of bisphosphonates and denosumab for men with advanced prostate cancer
Open Access
- 1 May 2014
- journal article
- review article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. 6, 217-24
Abstract
Prostate cancer is the most common cancer occurring in American men of all races. It is also the second leading cause of cancer death among men in the USA. Bone metastasis is a frequent occurrence in men with advanced prostate cancer, with skeletal-related events being a common complication and having negative consequences, leading to severe pain, increased health care costs, increased risk of death, and decreased quality of life for patients. Bone loss can also result from antiandrogen therapy, which can further contribute to skeletal-related events. Treatment with antiresorptive agents bisphosphonates, and the newly approved denosumab, a receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitor, has been shown to reduce the risk of skeletal-related complications and prevent treatment-induced bone loss in patients with advanced prostate cancer. This review discusses the role of antiresorptive agents bisphosphonates and RANK-L inhibitor in the current treatment of advanced prostate cancer by examining the primary literature and also focuses on the likely role of the bisphosphonates in the treatment of advanced prostate cancer in the future.Keywords
This publication has 32 references indexed in Scilit:
- Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice2012
- Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)European Journal of Cancer, 2012
- Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancerExpert Review of Pharmacoeconomics & Outcomes Research, 2012
- Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patientsSupportive Care in Cancer, 2012
- Treatment and prevention of bone complications from prostate cancerBone, 2011
- Pharmacologic Prevention of Skeletal-Related Events in Cancer PatientsOrthopedics, 2010
- Risk of Skeletal-Related Events in Patients with Advanced Prostate Cancer Treated with Pamidronate or Zoledronic AcidAnnals of Pharmacotherapy, 2010
- NCCN Task Force Report: Bone Health in Cancer CareJournal of the National Comprehensive Cancer Network, 2009
- Effect of bisphosphonates on pain and quality of life in patients with bone metastasesNature Reviews Clinical Oncology, 2009
- The role of bisphosphonates in the management of metastatic prostate cancer.Current Oncology Reports, 2003